fashion -WSS

fashion

author：entertainment 2025-09-05 13:32:25 - browse：3251

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Fauci's latest grilling in Congress: 9 hours, behind closed doors

hotspot

WSS

Severe heat forecast: Where scorching temperatures will persist over the next week

Nonprofit, backed by Microsoft, to certify AI tools in health care

What Henrietta Lacks's story taught me about my role as a doctor

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Doctors have an ethical obligation to be advocates

Hospital chaplains balance Covid safety with patients’ spiritual needs

focus

fashion

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Where does female orgasm come from? Scientists think they know

Supreme Court strikes down use of affirmative action

American taxpayers paid $1.8 trillion in health care costs in 2022

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Wildfire smoke exposes gaps in outdoor worker protections

FDA early review: GLP

BioMarin wins approval for gene therapy to treat hemophilia A

FDA early review: GLP

Wikipedia

Life science postdocs should get big pay hike, NIH panel says

STAT Virtual Event: JPM Recap, Live!

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Doctors have an ethical obligation to be advocates

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

hotspot

knowledge

leisure time